Stock listing

Agios Pharmaceuticals, Inc.

Selected listing: A1W2RM · LS · EUR · DE

Agios Pharmaceuticals, Inc. (Lang & Schwarz: A1W2RM), Health Technology. Latest release Jul 30, 2026: Agios Reports Second Quarter 2026 Financial Results…

A1W2RM:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A1W2RM
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Lang & Schwarz
Currency: EUR

Latest news from Agios Pharmaceuticals, Inc.

Agios Reports Second Quarter 2026 Financial Results and Provides Business Update

July 30, 2026

Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease

July 21, 2026

U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease

July 7, 2026

Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET

June 29, 2026

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

June 13, 2026

All Agios Pharmaceuticals, Inc. news →

Events

Replays

Agios Pharmaceuticals, Inc. (AGIO) Q2 2026 Earnings Call
Thu, Jul 30, 2026 · 08:00 AM ET
Watch
Agios Pharmaceuticals, Inc. (AGIO) Q1 2026 Earnings Call
Wed, Apr 29, 2026 · 08:00 AM ET
Watch
Agios Pharmaceuticals, Inc. (AGIO) Q4 2025 Earnings Call
Thu, Feb 12, 2026 · 08:00 AM ET
Watch

Research Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc. company profile

View the public company page for Agios Pharmaceuticals, Inc. on 6ix.

Agios Pharmaceuticals, Inc. news

Read company news and market updates connected to Agios Pharmaceuticals, Inc..

Agios Pharmaceuticals, Inc. investor events

Find investor webinars, events, and replay context for Agios Pharmaceuticals, Inc..